Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Significant Drop in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the target of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 58,200 shares, a decrease of 25.9% from the February 13th total of 78,500 shares. Currently, 0.5% of the company’s shares are sold short. Based on an average daily volume of 22,900 shares, the days-to-cover ratio is presently 2.5 days.

Indaptus Therapeutics Trading Up 0.9 %

NASDAQ INDP opened at $0.81 on Tuesday. The stock has a market cap of $11.47 million, a PE ratio of -0.48 and a beta of 1.60. Indaptus Therapeutics has a twelve month low of $0.70 and a twelve month high of $3.10. The stock has a fifty day simple moving average of $0.85 and a 200-day simple moving average of $1.07.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. Research analysts predict that Indaptus Therapeutics will post -1.79 EPS for the current year.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.